A Phase II Study of Tivozanib in Recurrent Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Tivozanib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 08 Jul 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Sep 2015 as per ClinicalTrials.gov record.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 29 May 2015 Primary endpoint has not been met (determine proportion of patients alive and progression free after 6) according to results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.